Hot flashes may not be managed adequately in patients treated for breast cancer
the ONA take:
According to a new study conducted by researchers at the University of Southampton in Southampton, United Kingdom, hot flashes experienced by women who have been treated for breast cancer are not being sufficiently addressed by clinicians and some of those women contemplate discontinuing estrogen receptor antagonists in order to stop the hot flashes.
The researchers sought to investigate the disparities between the symptoms the patient experiences and what the clinician recognized and manages. They conducted two surveys with physicians and their patients being treated for breast cancer. Of the physicians surveyed, 94% agreed that hot flashes are not managed adequately. Of the 666 women who were surveyed, 94% experienced hot flashes and 75% said they were a major issue in their life.
Only 25% reported speaking to a health care professional about their hot flashes. Furthermore, about one-third of women who experienced hot flashed contemplated discontinuing their medication to prevent the hot flashes from continuing to occur.
The findings suggest that hot flashes are not being managed adequately by physicians and patients should be encouraged to talk with their physician if they experience hot flashes.
Hot flashes are not being sufficiently addressed by clinicians.
Hot flushes are one of the most distressing conditions faced by women who have been treated for breast cancer, but they are not being adequately addressed by healthcare professionals and some women consider giving up their post cancer medication to try and stop them, a new study by the University of Southampton has shown.
More than 70 per cent of women who have had breast cancer experience menopausal problems, and hot flushes in particular, which are among the most prevalent and potentially distressing problems following breast cancer treatment. These can also be long lasting, persisting for more than five years once cancer treatment has ended and affecting all aspects of life, including sleep, social situations, intimate relationships and ability to work.
- Blood Test Predicts Stem Cell Transplant Success in Myelodysplastic Syndrome
- Immunotherapy and the Future of Prostate Cancer Treatment
- Elderly with NSCLC Can Tolerate Aggressive Radiation Therapy Treatments
- E-cigarettes and Replacement Nicotine Therapy Safer Than Tobacco Use
- Patients With Urologic Cancer Need Psycho-oncologic Support to Manage High Stress
- Lung Cancer Screening Rates Low Among Present and Former Smokers
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Patients Undergoing Multiple Systemic Therapies for Metastatic Prostate Cancer Expect a Cure
- FDA Grants Priority Review to Ceritinib for First-line Treatment of ALK+ NSCLC
- Overall Health Worse in African American Men Undergoing Active Surveillance For Prostate Cancer
- Clinical Benefit of Simtuzumab Inconsistent for Myelofibrosis
- Follow-up Rates in Active Surveillance for Prostate Cancer Higher in University-Based vs Safety-Net Hospitals
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|